-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Vessels within the thrombus resection (the EVT) acute ischemic cerebrovascular large vessel occlusion due to stroke outcome produces great changes
Vascular Thrombosis Stroke
One of the most important determinants after acute ischemic stroke is rapid reperfusion through intravenous thrombolysis, EVT, or both, to reduce the total cerebral ischemic time
In the past ten years, most time-efficiency studies have focused on dual functional results, only considering a single change in the disability status as important, rather than all changes that patients, family members, and doctors value as important
Most analyses of the time benefit of EVT emphasize the time interval from the onset/last known well (LKW) time to the last known health/onset to puncture (LKWTP)
To estimate the lifetime outcome related to the speed of intravascular thrombectomy in patients with acute ischemic stroke caused by large vessel occlusion (LVO)
Among the 781 patients treated with EVT, 406 (52.
In 298 of the 380 patients (78.
In patients with early treatment, the delay in the nursing process is related to the poorer clinical outcome of the LKW-intervention interval.
The important significance of this meta-analysis is the discovery that delays in care are related to the loss of healthy life years for patients with acute ischemic stroke treated with EVT, especially in the time period after arrival
Delays in care are related to the loss of healthy life-years for patients with acute ischemic stroke treated with EVT, especially in the time period after arrival
JAMA
is here to leave a message